|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PAFAH1B2 |
Gene summary for PAFAH1B2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PAFAH1B2 | Gene ID | 5049 |
| Gene name | platelet activating factor acetylhydrolase 1b catalytic subunit 2 | |
| Gene Alias | HEL-S-303 | |
| Cytomap | 11q23.3 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | P68402 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5049 | PAFAH1B2 | A002-C-205 | Human | Colorectum | FAP | 1.17e-04 | -2.39e-01 | -0.1236 |
| 5049 | PAFAH1B2 | A015-C-106 | Human | Colorectum | FAP | 2.00e-07 | -2.03e-01 | -0.0511 |
| 5049 | PAFAH1B2 | A002-C-114 | Human | Colorectum | FAP | 5.55e-03 | -1.99e-01 | -0.1561 |
| 5049 | PAFAH1B2 | A015-C-104 | Human | Colorectum | FAP | 1.06e-10 | -2.36e-01 | -0.1899 |
| 5049 | PAFAH1B2 | A001-C-014 | Human | Colorectum | FAP | 2.74e-02 | -8.74e-02 | 0.0135 |
| 5049 | PAFAH1B2 | A002-C-016 | Human | Colorectum | FAP | 3.17e-05 | -1.52e-01 | 0.0521 |
| 5049 | PAFAH1B2 | A001-C-203 | Human | Colorectum | FAP | 7.06e-05 | -1.88e-01 | -0.0481 |
| 5049 | PAFAH1B2 | A002-C-116 | Human | Colorectum | FAP | 1.39e-12 | -1.83e-01 | -0.0452 |
| 5049 | PAFAH1B2 | A014-C-008 | Human | Colorectum | FAP | 4.51e-02 | -1.91e-01 | -0.191 |
| 5049 | PAFAH1B2 | A018-E-020 | Human | Colorectum | FAP | 7.57e-04 | -2.42e-01 | -0.2034 |
| 5049 | PAFAH1B2 | F034 | Human | Colorectum | FAP | 1.06e-06 | -1.80e-01 | -0.0665 |
| 5049 | PAFAH1B2 | F072B | Human | Colorectum | FAP | 1.96e-04 | -1.74e-01 | 0.257 |
| 5049 | PAFAH1B2 | LZE4T | Human | Esophagus | ESCC | 3.20e-07 | 1.63e-01 | 0.0811 |
| 5049 | PAFAH1B2 | LZE5T | Human | Esophagus | ESCC | 8.66e-03 | -2.12e-02 | 0.0514 |
| 5049 | PAFAH1B2 | LZE8T | Human | Esophagus | ESCC | 5.96e-05 | 4.25e-02 | 0.067 |
| 5049 | PAFAH1B2 | LZE20T | Human | Esophagus | ESCC | 7.11e-10 | 7.84e-02 | 0.0662 |
| 5049 | PAFAH1B2 | LZE24T | Human | Esophagus | ESCC | 5.21e-12 | 1.77e-01 | 0.0596 |
| 5049 | PAFAH1B2 | P1T-E | Human | Esophagus | ESCC | 1.13e-02 | -2.55e-03 | 0.0875 |
| 5049 | PAFAH1B2 | P2T-E | Human | Esophagus | ESCC | 1.55e-19 | 1.50e-01 | 0.1177 |
| 5049 | PAFAH1B2 | P4T-E | Human | Esophagus | ESCC | 8.14e-26 | 5.85e-01 | 0.1323 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0009896 | Colorectum | AD | positive regulation of catabolic process | 180/3918 | 492/18723 | 4.33e-16 | 1.94e-13 | 180 |
| GO:0031331 | Colorectum | AD | positive regulation of cellular catabolic process | 156/3918 | 427/18723 | 4.68e-14 | 1.05e-11 | 156 |
| GO:0010506 | Colorectum | AD | regulation of autophagy | 111/3918 | 317/18723 | 3.57e-09 | 2.35e-07 | 111 |
| GO:0016236 | Colorectum | AD | macroautophagy | 103/3918 | 291/18723 | 6.76e-09 | 4.15e-07 | 103 |
| GO:0016042 | Colorectum | AD | lipid catabolic process | 97/3918 | 320/18723 | 4.31e-05 | 7.56e-04 | 97 |
| GO:0016241 | Colorectum | AD | regulation of macroautophagy | 50/3918 | 141/18723 | 4.55e-05 | 7.92e-04 | 50 |
| GO:0010508 | Colorectum | AD | positive regulation of autophagy | 43/3918 | 124/18723 | 2.64e-04 | 3.27e-03 | 43 |
| GO:00098961 | Colorectum | SER | positive regulation of catabolic process | 132/2897 | 492/18723 | 4.16e-11 | 6.72e-09 | 132 |
| GO:00313311 | Colorectum | SER | positive regulation of cellular catabolic process | 114/2897 | 427/18723 | 1.22e-09 | 1.27e-07 | 114 |
| GO:00162361 | Colorectum | SER | macroautophagy | 79/2897 | 291/18723 | 1.97e-07 | 1.10e-05 | 79 |
| GO:00160421 | Colorectum | SER | lipid catabolic process | 77/2897 | 320/18723 | 3.52e-05 | 9.18e-04 | 77 |
| GO:00105061 | Colorectum | SER | regulation of autophagy | 74/2897 | 317/18723 | 1.39e-04 | 2.77e-03 | 74 |
| GO:00162411 | Colorectum | SER | regulation of macroautophagy | 34/2897 | 141/18723 | 4.74e-03 | 3.72e-02 | 34 |
| GO:00098962 | Colorectum | MSS | positive regulation of catabolic process | 163/3467 | 492/18723 | 3.10e-15 | 9.22e-13 | 163 |
| GO:00313312 | Colorectum | MSS | positive regulation of cellular catabolic process | 140/3467 | 427/18723 | 7.02e-13 | 1.33e-10 | 140 |
| GO:00162362 | Colorectum | MSS | macroautophagy | 93/3467 | 291/18723 | 2.08e-08 | 1.17e-06 | 93 |
| GO:00105062 | Colorectum | MSS | regulation of autophagy | 95/3467 | 317/18723 | 4.36e-07 | 1.71e-05 | 95 |
| GO:00162412 | Colorectum | MSS | regulation of macroautophagy | 44/3467 | 141/18723 | 1.88e-04 | 2.64e-03 | 44 |
| GO:00160422 | Colorectum | MSS | lipid catabolic process | 77/3467 | 320/18723 | 7.43e-03 | 4.71e-02 | 77 |
| GO:00098964 | Colorectum | FAP | positive regulation of catabolic process | 126/2622 | 492/18723 | 3.76e-12 | 2.56e-09 | 126 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PAFAH1B2 | SNV | Missense_Mutation | c.185T>G | p.Leu62Arg | p.L62R | P68402 | protein_coding | tolerated(0.06) | benign(0.113) | TCGA-LL-A7SZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR | |
| PAFAH1B2 | SNV | Missense_Mutation | novel | c.83A>T | p.His28Leu | p.H28L | P68402 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-A6-5657-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Ancillary | leucovorin | SD |
| PAFAH1B2 | insertion | Nonsense_Mutation | novel | c.372_373insTAGATGAAA | p.Leu124_Ile125insTer | p.L124_I125ins* | P68402 | protein_coding | TCGA-AM-5820-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| PAFAH1B2 | deletion | Frame_Shift_Del | c.190delT | p.Ser64ProfsTer6 | p.S64Pfs*6 | P68402 | protein_coding | TCGA-AZ-4615-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | xeloda | PD | |||
| PAFAH1B2 | SNV | Missense_Mutation | c.77N>A | p.Ser26Tyr | p.S26Y | P68402 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PAFAH1B2 | SNV | Missense_Mutation | rs747423610 | c.322G>A | p.Glu108Lys | p.E108K | P68402 | protein_coding | tolerated(0.33) | benign(0.018) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| PAFAH1B2 | SNV | Missense_Mutation | novel | c.508N>A | p.Val170Met | p.V170M | P68402 | protein_coding | deleterious(0.04) | probably_damaging(0.959) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
| PAFAH1B2 | SNV | Missense_Mutation | c.262G>A | p.Gly88Arg | p.G88R | P68402 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-B5-A0K6-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| PAFAH1B2 | SNV | Missense_Mutation | novel | c.259A>C | p.Asn87His | p.N87H | P68402 | protein_coding | deleterious(0.03) | probably_damaging(0.959) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| PAFAH1B2 | SNV | Missense_Mutation | novel | c.358N>A | p.Ala120Thr | p.A120T | P68402 | protein_coding | tolerated(0.31) | benign(0.414) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |